Genetic CRC risk likely mediated by differential adenoma risk

Genetic CRC risk likely mediated by differential adenoma risk
Much of the genetic risk for colorectal cancer in the general population is mediated by differential adenoma risk, according to research published in the January issue of Gastroenterology.

(HealthDay)—Much of the genetic risk for colorectal cancer (CRC) in the general population is mediated by differential adenoma risk, according to research published in the January issue of Gastroenterology.

Luis G. Carvajal-Carmona, Ph.D., from the University of Oxford in the United Kingdom, and colleagues analyzed genotype data from 1,755 adenoma cases and 3,976 controls with no colorectal disease for 18 CRC single-nucleotide polymorphisms (SNPs).

The researchers found that eight of 18 known CRC-associated SNPs (rs10936599, rs6983267, rs10795668, rs3802842, rs4444235, rs1957636, rs4939827, and rs961253) were over-represented in CRC-free patients with adenomas, compared with controls. There was no significant association with adenoma risk with the other CRC-associated SNPs (rs6691170, rs6687758, rs16892766, rs7136702, rs11169552, rs4779584, rs9929218, rs10411210, rs4813802, and rs4925386).

" to CRC in the general population is likely to be mediated in part by predisposition to ," the authors write. "In principle, especially if further studies can assign SNPs as adenoma-predisposing, carcinoma-predisposing, or both, such variation could be used to modulate population-based CRC-prevention measures, in a way analogous to the different
methods of prophylaxis used for familial adenomatous polyposis and Lynch syndrome."

Pfizer and Merck both contributed funding to this research.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Reduced efficacy for CRC screenings done by non-GI docs

Jun 22, 2012

(HealthDay) -- Having interval colorectal cancer (CRC) colonoscopy screenings performed by nongastroenterologists compared with gastroenterologists (GIs) results in a noticeable reduction in the long-term ...

Recommended for you

How a common antacid could lead to cheaper anti-cancer drugs

9 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.